Minimum Inhibitory Concentration of Augmentin on Nasal Staphylococcus aureus Isolates Among Undergraduate Students
[1]
Orhue O. P., Department of Microbiology, Faculty of Natural Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria.
[2]
Oikhala O. G., Department of Microbiology, Faculty of Natural Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria.
[3]
Agbolahor D. E., Department of Microbiology, Faculty of Natural Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria.
[4]
Ekundayo A. O., Department of Microbiology, Faculty of Natural Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria.
[5]
Oviasojie F. E., Department of Microbiology, Faculty of Natural Sciences, Ambrose Alli University, Ekpoma, Edo State, Nigeria.
Although Staphylococcus aureus (S. aureus) can be a human commensal, it is a cause of bacterial infections and carries mortality rate of over 30% despite the advancement in the 21st century therapeutics. This is in addition to the growing prevalence of drug resistance that has made treatment with antibiotic to become more problematic. To fight this growing problem of antibiotic, antibiotics combination therapy was adopted as a strategies and this lead to several combination therapy. This study therefore investigates the Minimum inhibitory concentration (MIC) of an antibiotics combination therapy such as Augmentin on nasal S. aureus isolates. Of interest however is Augmentin; an oral antibacterial combination consisting of amoxicillin and clavulanate potassium. The study was conducted among apparently healthy undergraduate students of Ambrose Alli University, Ekpoma. Following standard laboratory procedures, biochemical characterization and Augmentin antibiotic susceptibility testing were carried out on 12 samples of S. aureus isolates. The results showed that nasal S. aureus isolates were positive to coagulase, mannitol, sucrose and catalase but negative to indole, urease and oxidase tests. Overall, all the isolates were susceptible to varying concentrations of Augmentin antibiotic with the minimum MIC and maximum MIC observed at 0.05µg/ml and 12.5µg/ml respectively. The mean MIC of Augmentin antibiotic was 5.16±5.69µg/ml. There was a statistical significant different in the MIC between the 12 samples. The wide variation in the minimum and maximum MICs (12.45µg/ml) with Augmentin antibiotic suggests a wide variation in dosage of Augmentin antibiotic capable of inhibiting the growth of microorganism such as S.aureus after overnight incubation.
Augmentin, Minimum Inhibitory Concentration, Staphylococcus aureus, Undergraduate Students
[1]
Adegoke AA, and Komolafe AO. Multi-drug resistant Staphylococcus aureus in clinical cases in Ile-Ife, Southwest Nigeria. International Journal of Medicine and Medical Sciences. 2009; 1. (3) pp. 068-072.
[2]
Adeleke O E, Ogunniyi O A and Olarinde J D. Susceptibility of some Gram-positive and Gram-negative bacteria against some brands of amoxicillin-clavulanic acid. N Y Sci J 2014;7(6):80-86.
[3]
Adesida, S.A., Abioyi, O.A., Banero, B.S., Brai, B.T.C., Smith, S.I., Amisu, K.O., Ehichioya, D.U., Ogunsola, E.T. and Coker, A.O. (2007). Associated risk factors and pulse-field gel electrophoresis of nasal isolated of Staphylococcus aureus from medical students in a tertiary hospital in Lagos, Nigeria. Brazilian J Infect. Dis., 11(1):
[4]
Alsaimary IE, Alabbasi AM, Najim JM (2010). Antibiotics Susceptibility of bacterial pathogens Associated with otitis media. J. Bacteria Res., 2(4): 41-50.
[5]
Arshad HM, Mohiudin AO, Azmi BM. Comparative in vitro antibacterial analysis of different brands of cefixime against isolates of Staphylococcus aureus and Escherichia coli. Journal of Applied Pharmaceutical Science 2012; 2(1):109-113
[6]
Bahashwan, A.S. and El Shafey, M.H. (2013). Antimicrobial resistance patterns of Proteus isolates from clinical specimens. European Scientific Journal; vol.9, No.27: 188-202.
[7]
Baliga, S., Bansil, R., Suchitra, V., Bharati, B., Vidyaniketan, K. and Shenoy, S. (2007). Nasal carriage of MRSA in medical students. J. Hosp. Infect., 91-92.
[8]
British National Formulary. Infection. British Medical Association and Royal Pharmaceutical Society of Great Britain London: UK. 1999; pp 246.
[9]
Brown AF, Leech JM, Rogers TR and Mcloughlin RM. Staphylococcus aureus colonisation: modulation of host immune response and impact on human vaccine design. Frontiers in Immunology, 2013; 4:507.
[10]
Bush K. Beta lactamase Inhibitors. World report 2003; 21.
[11]
Cruickshank, R., Duguid, J.P., Marmiun, J.P and Swam, R.H. (1975), Staphylococcus aureus, Medical Micro biology -13th edition. Livingston Publishers Pp 236-245.
[12]
Couto I, Melo-cristino J, Fernades ML. Unusually Large Number of Methicillin-Resistant Staphylococcus aureus Clones in a Portuguese Hospital Dois: 2000; 101016/50, 40-6736(01)08713-5.
[13]
David MD, Kearus AM, Gossain S, Ganner M, Holmes A (2006). Community – associated methicillin – resistant Staphylococcus aureus: nosocomial transmission in a neonatal unit. J. Hosp. Infect. 64: 244-250.
[14]
Emeka L.I., Emeka P.M. and Okoli, C.L. (2013). Evaluation of antibiotic susceptibility of Staphylococcus aureus isolated from nasal and thumb prints of University students and their resistance pattern. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS); Volume 5, Issue 5, PP 59-64.
[15]
Feglo P.K., Gbedema S.Y., Quay S.N.A., Adu-Sarkodie Y., and C. Opoku-Okrah (2010). Occurrence, species distribution and antibiotic resistance of Proteus isolates: A case study at the Komfo Anokye Teaching Hospital (KATH) in Ghana. International Journal of Pharma Sciences and Research (IJPSR), 1(9): 347-352.
[16]
Hannah A, Saleem, S Chaudhary, S Barkaat, M, Arshad MU., Anti-bacterial activity of Nigella sativa and clinical isolates of methicillin resistant Staphylococcus aureus. Journal of Ayub Medical College Abbottabad 2008; 20(3);72-74
[17]
Hotu B, Ellenbogen C, Hayden MK, Aroutcheva A, Rice TW, Weinstein RA. Community– associated methicillin–resistant Staphylococcus aureus skin and soft tissue infections at a publichospital: do public housing and incarceration amplify transmission? Arch. Intern. Med. 2007; 167: 1026-1033.
[18]
Kolawole DS, Stratton CW, Zygmunt DJ. Characterisation of four BetaLactamases produced by Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 1992; 36: 440-5.
[19]
Kluytmans, J.A.J.W., Mouton, J.W., IJzerman, E.P.F., Vandenbroucke-Grauls, C.M.J.E., Maat, A.W.P.M., Wagenvoort, J.H.T., and Verbrugh, H.A. Nasal carriage of S. aureus as a major risk factor for wound infections after cardiac surgery. J. Infect. Dis., 1995; 171:216–219.
[20]
Lamikanra, B. D. Paul, O. B. Akinwole and M. O. Paul (2006) Nasal carriage of Staphylococcus aureus in a population of healthy Nigerian students., J Med Microbiol 55 , 317-324.
[21]
Melzer, M., and Welch, C. Thirty-day mortality in UK patients with community-onset and hospital acquired meticillin-susceptible Staphylococcus aureus bacteraemia. J Hosp Infect., 2013.
[22]
Nester EW, Evans CR, Nancy P, Denise GA, Martha TT (2004). The Genus: Staphylococcus In: Nester EW ed. Microbiology – a Human Perspective. 2nd McGrew Hill, New York, pp. 693-695.
[23]
Odulaja JO, Azubuike CP, Akinleye MO. Quality assessment of amoxicillin-clavulanate potassium tablets in Lagos, Nigeria. Journal of Chemical and Pharmaceutical Research 2012, 4(12):5032-5038.
[24]
Ojo KK, Sapkota AR, Ojo TB, Pottinger PS: Antimicrobial resistance gene distribution: A socioeconomic and sociocultural perspective. GMS German Medical Science. 2008, 3: Doc 26.
[25]
Okeke IN, Aboderin OA, Byarugaba DK, Ojo KK, Opintan JA. Growing problem of multidrug-resistant enteric pathogens in Africa. Emerging Infectious Diseases. 2007, 13:1640-1646.
[26]
Okunye O.L., Adeleke O.E., Adegoke O.A. and Adeyemi O.H. (2011). Antibiotic Susceptibility Pattern and Beta-lactamase Production in Isolates of Staphylococcus aureus from Recurrent Furunculosis in Southwestern, Nigeria. ©Sierra Leone Journal of Biomedical Research; Vol. 3(3) pp. 123-127.
[27]
Olayemi, J, Olayinka BO, Musa AI. Evaluation of antibiotic self-Medication Pattern amongst undergraduate students of Ahmadu Bello University (Main Campus), Zaria. Res. J. Appl. Sci. Eng. Technol., 2010 2(1): 35-38.
[28]
Orhue, P.O. and Momoh A.R.M. (2012). The antibiogram types of Staphylococcus aureus isolated from nasal carriers from irrua Specialist teaching hospital, Edo state, Nigeria. E3 Journal of Biotechnology and Pharmaceutical Research Vol. 3(4), pp. 83-87.
[29]
Plested SJ, Simpson IN, James M. (1983). The Detection of Bacterial β- Lactamase and their Identification by Analytical Isoelectric focusing. In: Russel AD and Quensel LB. editors. Antibiotics: Assessment and Antimicrobial Activity and Resistance. London: Academic Press 1983; 111-26.
[30]
Sampathukumar P. Methicillin-Resistant Staphylococcus aureus: The latest Health Scare. Moyo Clin Proc. 2007; 82: 1403-1467.
[31]
Santhosh, DV., Shobha, KL., Bairy, I., Rao, G. ,Anand, KM and D’ Souza,J: Nasal screening and survey of pre-clinical medical students from Malaysia for nasal carriage of coagulase positive MRSA and rate of nasal colonization with Staphylococcus species Journal of Clinical and Diagnostic Research. 2007 Dec; 1(6):494-499.
[32]
Sapkota AR, Coker ME, Rosenberg Goldstein RE, Atkinson NL, Sweet SJ, Sopeju PO, Ojo MT, Otivhia E, Ayepola OO, Olajuyigbe OO,. Self-medication with antibiotics for the treatment of menstrual symptoms in Southwest Nigeria: a cross-sectional study. BMC Public Health 2010, 10:610.
[33]
Shanmugam J., Gopal R., Kumar S.S. (2009). The prevalence, antibiogram and characterisation of staphylococcus aureus including MRSA among the healthy staff, medical students and patients from Sri Manakula Vinayagar Medical College and Hospital (SMVMCH), Puducherry. DSTE project report (Government of Puducherry).
[34]
Thomson KS. Controversies about Extended Spectrum and AmpC BetaLactamases. Emerging Infecti Dis 2001; 7: 333-6.
[35]
Yzerman, E.P.F., Boelens, H.A.M., Tjhie, J.H.T., Kluytmans, J.A.J.W., Mouton, J.W. and Verbrugh, A.H. (1996). DAPACHE II for predicting course and outcome of nosocomial S. aureus bacteremia and its relation to host defense. J. Infect. Dis.; 173:914–919.
